Manila Times Business
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire RayThera Inc. for up to $1 billion, cons
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trump, Iran's president sign deal to end Mideast war
2h ago
SK hynix Ships Samples of 12-Layer Next-Gen 'HBM4E'
2h ago
Chinese Short Drama The Lady from the Northeast Season 2 Gains Popularity in Malaysia, Showcasing Compelling Sino-Malaysian Cultural Exchanges
2h ago
Kepwealth calls for annual stockholders meeting
2h ago